|
|
Volumn 25, Issue 7, 2007, Pages 699-700
|
|
Industry waits for fallout from Cabilly
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
CETUXIMAB;
ETANERCEPT;
INFLIXIMAB;
PALIVIZUMAB;
RITUXIMAB;
TRASTUZUMAB;
BIOTECHNOLOGY;
COURT;
DECISION MAKING;
DRUG INDICATION;
DRUG INDUSTRY;
LEGAL ASPECT;
LICENSING;
NOTE;
PATENT;
PRIORITY JOURNAL;
ANTIBODIES, MONOCLONAL;
BIOTECHNOLOGY;
HUMANS;
INDUSTRY;
PATENTS;
RESEARCH SUPPORT;
RISK;
|
|
EID: 34447317512
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0707-699 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
